Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Inventory (2023 - 2025)

Historic Change in Inventory for Tarsus Pharmaceuticals (TARS) over the last 3 years, with Q3 2025 value amounting to -$37000.0.

  • Tarsus Pharmaceuticals' Change in Inventory fell 10567.48% to -$37000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $988000.0, marking a year-over-year decrease of 8158.43%. This contributed to the annual value of $2.0 million for FY2024, which is 3414.87% down from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Change in Inventory of -$37000.0 as of Q3 2025, which was down 10567.48% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Change in Inventory ranged from a high of $3.1 million in Q4 2023 and a low of -$227000.0 during Q4 2024
  • Moreover, its 3-year median value for Change in Inventory was $652000.0 (2024), whereas its average is $707555.6.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' Change in Inventory in the last 5 years was 424666.67% (2024), contrasted with its biggest fall of 10734.15% (2024).
  • Over the past 3 years, Tarsus Pharmaceuticals' Change in Inventory (Quarter) stood at $3.1 million in 2023, then tumbled by 107.34% to -$227000.0 in 2024, then surged by 83.7% to -$37000.0 in 2025.
  • Its Change in Inventory stands at -$37000.0 for Q3 2025, versus $1.2 million for Q2 2025 and $84000.0 for Q1 2025.